BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 15.4//EN
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
DTSTART;VALUE=DATE:20250101
TZNAME:UTC
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Date:&nbsp\;Wednesday 15th May 2024\nTime:&nbsp\;15:00-16:30 BS
 T | 16:00-17:30 CEST\nLocation:&nbsp\;Online via Zoom\nSpeakers:&nbsp\;Eli
 zabeth Garner (Ferring Pharmaceuticals US)\,&nbsp\;Christoph Gerlinger (Ba
 yer)\,&nbsp\;Radu Cimpeanu&nbsp\;(University of Warwick) and&nbsp\;Jack Wi
 lkinson&nbsp\;(Manchester University).\n\nWho is this event intended for?&
 nbsp\;Statisticians\, data analysts and researchers with an interest in un
 derstanding the challenges and opportunities in drug development for Women
 &rsquo\;s Health.\nWhat is the benefit of attending?&nbsp\;Learning from t
 he experiences of a clinician and statisticians working in the field of wo
 men&rsquo\;s health.\nRegistration\nThis event is free of charge to both M
 embers of PSI and Non-Members. To register your place for this event\, ple
 ase click here.&nbsp\;\nOverview\nThis multidisciplinary webinar will cove
 r the latest insights in women's health. Our panel of clinicians\, statist
 icians and mathematicians will provide valuable perspectives on current ch
 allenges and opportunities in the field covering recent developments in wo
 men&rsquo\;s health drug development\, statistical complexities of in vitr
 o fertilization (IVF) and insights into the statistical considerations sur
 round the menstrual cycle and menstrual bleeding measurements.\n\nOur este
 emed panel will present on the following topics:\n● Opening on drug develo
 pment in women&rsquo\;s health - Elizabeth Garner (Ferring Pharmaceuticals
  US)\n● Menstrual cycle and Measurement of menstrual bleeding - Christoph 
 Gerlinger (Bayer)\n●&nbsp\;A new flow-based design for double-lumen needle
 s in IVF - Radu Cimpeanu (University of Warwick)\n● &lsquo\;IVF &ndash\; s
 tatistical challenges in complex\, multistage interventions&rsquo\;? - Jac
 k Wilkinson (Manchester University)\n\n\nSpeaker details\n\n\n\n    \n    
     \n            \n            Speaker\n            \n            \n     
        Biography\n            \n            \n            Abstract\n      
       \n        \n        \n            \n            \n            Elizab
 eth Garner\n            \n            \n            Elizabeth Garner is a 
 seasoned pharmaceutical executive with a career-long focus on addressing u
 nsolved issues and conditions that affect women&rsquo\;s health and qualit
 y of life. Dr. Garner is currently Chief Scientific Officer of Ferring Pha
 rmaceuticals US and has held previous positions as Chief Medical Officer o
 f ObsEva and Agile Therapeutics\, and senior positions at Myriad Genetics\
 , Abbott Laboratories\, and Merck Research Labs. Beth is on the Boards of 
 Directors of Kezar Life Sciences and Sermonix Pharmaceuticals and is the C
 hair of the Board of NUA Surgical. She is also the Immediate Past Presiden
 t of the American Medical Women&rsquo\;s Association (AMWA)\, a profession
 al organization whose mission is to advance women in medicine\, advocate f
 or equity\, and ensure excellence in healthcare. Dr. Garner received her M
 .D. and M.P.H. degrees from Harvard Medical School and the Harvard School 
 of Public Health and trained in Obstetrics and Gynecology and Gynecologic 
 Oncology at Brigham and Women&rsquo\;s and Massachusetts General Hospitals
  and the Dana Farber Cancer Institute. Beth is a frequent speaker on a ran
 ge of topics including the health of women\, women&rsquo\;s leadership\, a
 nd clinical trial diversity\; she is a 2019 and 2023 awardee of the Pharma
 Voice 100 Most Inspiring Individuals in the life sciences industry and was
  the 2022 recipient of the Woman in Science Award from AMWA.\n            
 \n            \n            Opening on drug development in women's health\
 n            Women&rsquo\;s health is defined as conditions that 1) affect
  women distinctly (e.g.\, endometriosis)\, 2) affect women differently (e.
 g.\, heart disease)\, and 3) affect women disproportionately (e.g.\, autoi
 mmune disease). Although women make up half of the world&rsquo\;s populati
 on\, inclusion of women in clinical trials in the US has only been require
 d since 1993. Furthermore\, there has been a lack of investment in women&r
 squo\;s health research. According to McKinsey\, in 2020\, only 1% of the 
 almost $200 billion in investment in healthcare research and innovation we
 nt toward female-specific conditions beyond oncology. The consequence of t
 hese factors is that despite the exponential increase in the generation of
  data in health\, substantial data gaps in women&rsquo\;s health persist. 
 In November 2023\, the White House announced a new initiative focused on W
 omen&rsquo\;s Health Research. In February of this year\, Jill Biden\, who
  is leading the White House Initiative\, announced $100 million in federal
  funding for research and development in women&rsquo\;s health\, opening u
 p a new era in which women&rsquo\;s health is no longer considered a &ldqu
 o\;niche&rdquo\; market.\n            &nbsp\;\n            \n        \n   
      \n            \n            \n            Christoph Gerlinger\n      
       \n            \n            Christoph works since more than 30 years
  as a statistician in the pharmaceutical industry. He is Bayer&rsquo\;s ex
 pert statistician for Womens&rsquo\; Healthcare and for Health Technology 
 Assessment. Christoph is an EFSPI council member and since over 10 years t
 he regulatory chair of EFSPI. He is also member of several scientific advi
 sory groups for EMA and the European Commission. In his spare time Christo
 ph teaches experimental gynaecology at the Saarland State University and l
 eads the local chapter of the pan-European party Volt.\n            &nbsp\
 ;\n            Christoph&rsquo\;s involvement in women&rsquo\;s health sta
 rted when he joined Schering AG in 1996. His Ph.D. thesis was entitled &ld
 quo\;Development of two methodological guidelines for the evaluation of bl
 eeding patterns &ndash\; A tool for registration and prescription on the b
 asis of an empirical analysis&rdquo\;. Christoph (co-)authored many papers
  on methodological topics in women&rsquo\;s health and he is also a co-dev
 eloper of several PRO instruments in the field of women&rsquo\;s health.\n
             \n            \n            Menstrual cycle and Measurement of
  menstrual bleeding\n            The talk will start with a brief introduc
 tion into the female menstrual cycle aimed primarily at the layMEN. The as
 sessment and statistical analysis of the normal menstrual bleeding pattern
  will be described. Special attention will be given to changes in bleeding
  patterns introduced by hormonal birth control products. First\, analyses 
 of bleeding patterns for products with scheduled bleeding\, such as the cl
 assical &ldquo\;pill&rdquo\;\, will be addressed. Then\, bleeding pattern 
 analyses for products without scheduled bleeding\, such as intrauterine de
 vices\, aka &ldquo\;the coil&rdquo\;\, will be discussed. While bleeding p
 attern analyses for contraceptives are typically based on simple questions
  like bleeding &ldquo\;yes&rdquo\; / &ldquo\;no&rdquo\;\, for the investig
 ation of abnormal menstrual bleeding the actual amount of the bleeding in 
 mL (or in uk fl oz) is of interest. Previously\, this required the collect
 ion of all items for sanitary protection\, i.e.\, pads and tampons\, used 
 during a cycle and shipping them to a laboratory for chemical analysis. To
 day\, a validated pictogram is available where the woman rates on a simple
  Likert scale how soiled her sanitary protection item was. The elaboration
  and validation of this method will be presented.\n            \n        \
 n        \n            \n            \n            Radu Cimpeanu\n        
     \n            \n            Dr. Radu Cimpeanu is Associate Professor (
 Reader) in Applied Mathematics at the University of Warwick\, specialising
  in the mathematical modelling of real-world systems. His primary research
  interests lie at the interface between fluid mechanics\, scientific compu
 ting and numerical solutions for partial differential equations\, with a p
 articular interest in knowledge transfer and industrial mathematics (and a
  keen supporter of the Study Groups with Industry format). Radu has so far
  developed methodologies used to address technologically relevant problems
  in areas such as microfluidics\, aircraft surface de-icing and spray atom
 isation. He is currently Deputy Director of the Warwick Fluid Dynamics Res
 earch Centre\, and Executive Committee member of the UK Fluids Network\, w
 hile also supporting the UKRI National Fellowships in Fluid Dynamics (NFFD
 y) programme.\n            \n            \n            A new flow-based de
 sign for double-lumen needles in IVF\n            \n            Oocyte ret
 rieval forms a crucial part of in vitro fertilisation treatment and its ul
 timate outcome. Standard double-lumen needles\, which include a sequence o
 f aspiration and flushing steps\, are characterised by a similar success r
 ate to single-lumen needles\, despite their increased cost. In this talk I
  will present a novel hydrodynamics-based needle called the OxIVF needle\,
  with design features that enablethe generation of an internal flow field 
 within the full follicular volume via laterally\, rather than frontally\, 
 oriented flushing\, leading to successful retrievals with no additional st
 ress on the oocyte. An in-silico mathematical model (J. Biomechanics 160\,
  111832\, 2023) based on multi-phase flow direct numerical simulation prov
 ides new insight into the internal flow movement as part of the constructe
 d digital twin\, while forces measured during these tests showcase how the
  oocyte experiences stresses which are no larger than at the aspiration po
 int\, with the flow field providing a gentle steering effect towards the e
 xtraction region. We found that the proposed framework increases oocyte yi
 eld to up to 100% in computational studies\, marking a significant improve
 ment over the traditional double-lumen design whose success rate of no mor
 e than 75% in like-for-like comparisons was also highly dependent on the l
 ocation of the needle tip inside the follicle. This design unlocks new cap
 abilities in both human and veterinary contexts\, with preliminary studies
  showing significant promise (Animal - science Proc. 14 (3)\, 468-469\, 20
 23). The interdisciplinary approach and research team dynamics\, which und
 erpinned many of the advances above\, will also be brought to the forefron
 t as the scientific milestones of the study are expanded upon. Acknowledgm
 ents: Alfonso A. Castrej&oacute\;n-Pita (University of Oxford)\, Lee Nai L
 im (Oxford University Hospital)\, Manu Vatish (University of Oxford) and E
 ktoras X. Georgiou (Oxford University Hospital).\n            \n        \n
         \n            &nbsp\;Jack Wilkinson\n            \n            Jac
 k Wilkinson is a Senior Lecturer in the Centre for Biostatistics\, Univers
 ity of Manchester. His research interests cover both the application\, dev
 elopment\, and criticism of methods for the evaluation of health intervent
 ions\, with a particular interest in interventions for the treatment of su
 bfertility\, including assisted reproductive technologies (ART). He holds 
 Statistics or Methodological Editor roles for Cochrane Gynaecology and Fer
 tility\, BJOG: An International Journal of Obstetrics and Gynaecology\, Fe
 rtility and Sterility and Reproduction and Fertility. He is currently lead
 ing the NIHR-funded INSPECT-SR project\, which aims to develop a tool for 
 identifying &lsquo\;problematic&rsquo\; randomised controlled trials\, inc
 luding those subject to data fabrication or falsification.\n            \n
             IVF &ndash\; statistical challenges in complex\, multistage in
 terventions - Jack Wilkinson (Manchester University)\n            \n      
       Assisted Reproductive Technologies (ART) are complex multi-stage int
 erventions\, typically involving stimulation of ovaries and collection of 
 eggs\, the fertilisation of eggs to make embryos\, the culture and subsequ
 ent selection of embryos using some form of algorithm\, followed by an emb
 ryo transfer with the aim of producing a pregnancy and subsequent live bir
 th of a healthy infant. The multistage nature of ART introduces a number o
 f challenges for the design and analysis of both randomised and non-random
 ised studies of fertility interventions\, and some apparently &lsquo\;comm
 on-sense&rsquo\; analysis choices correspond to no clinically relevant est
 imand. In this talk\, I will give a non-technical overview of some recurri
 ng methodological pitfalls in ART intervention research.\n            \n  
       \n    \n\n&nbsp\;\n\n
DTEND:20240515T153000Z
DTSTAMP:20261116T002119Z
DTSTART:20240515T140000Z
LOCATION:
SEQUENCE:0
SUMMARY:PSI Webinar: Drug Development in Women's Health
UID:RFCALITEM639303852794873882
X-ALT-DESC;FMTTYPE=text/html:<strong>Date:</strong>&nbsp\;Wednesday 15th Ma
 y 2024<br />\n<strong>Time:</strong>&nbsp\;15:00-16:30 BST | 16:00-17:30 C
 EST<br />\n<strong>Location:</strong>&nbsp\;Online via Zoom<br />\n<strong
 >Speakers:</strong>&nbsp\;Elizabeth Garner<em> (Ferring Pharmaceuticals US
 )\,&nbsp\;</em>Christoph Gerlinger <em>(Bayer)\,&nbsp\;</em>Radu Cimpeanu&
 nbsp\;<em>(University of Warwick) </em>and&nbsp\;Jack Wilkinson<em><em>&nb
 sp\;(Manchester University).</em></em><br />\n<br />\n<strong>Who is this 
 event intended for?&nbsp\;</strong>Statisticians\, data analysts and resea
 rchers with an interest in understanding the challenges and opportunities 
 in drug development for Women&rsquo\;s Health.<strong><br />\nWhat is the 
 benefit of attending?&nbsp\;</strong>Learning from the experiences of a cl
 inician and statisticians working in the field of women&rsquo\;s health.<b
 r />\n<h4>Registration</h4>\n<p>This event is free of charge to both Membe
 rs of PSI and Non-Members. To register your place for this event\, please 
 <strong><a href="https://psi.glueup.com/event/psi-webinar-drug-development
 -in-womens-health-100847/" target="_blank"><span style="text-decoration: u
 nderline\;">click here</span></a></strong>.&nbsp\;</p>\n<h4>Overview</h4>\
 n<p>This multidisciplinary webinar will cover the latest insights in women
 's health. Our panel of clinicians\, statisticians and mathematicians will
  provide valuable perspectives on current challenges and opportunities in 
 the field covering recent developments in women&rsquo\;s health drug devel
 opment\, statistical complexities of in vitro fertilization (IVF) and insi
 ghts into the statistical considerations surround the menstrual cycle and 
 menstrual bleeding measurements.<br />\n<br />\n<span style="text-decorati
 on: underline\;">Our esteemed panel will present on the following topics</
 span>:<br />\n● Opening on drug development in women&rsquo\;s health - Eli
 zabeth Garner (Ferring Pharmaceuticals US)<br />\n● Menstrual cycle and Me
 asurement of menstrual bleeding - Christoph Gerlinger (Bayer)<br />\n●&nbs
 p\;A new flow-based design for double-lumen needles in IVF - Radu Cimpeanu
  (University of Warwick)<br />\n● &lsquo\;IVF &ndash\; statistical challen
 ges in complex\, multistage interventions&rsquo\;? - Jack Wilkinson (Manch
 ester University)<br />\n<br />\n</p>\n<h4>Speaker details</h4>\n<table bo
 rder="1" cellspacing="0" cellpadding="0">\n</table>\n<table class="table t
 able-striped table-bordered">\n    <tbody>\n        <tr>\n            <td 
 valign="top" style="width: 123px\;">\n            <p><strong>Speaker</stro
 ng></p>\n            </td>\n            <td valign="top" style="width: 227
 px\;">\n            <p><strong>Biography</strong></p>\n            </td>\n
             <td valign="top" style="width: 252px\;">\n            <p><stro
 ng>Abstract</strong></p>\n            </td>\n        </tr>\n        <tr>\n
             <td valign="top" style="width: 123px\;">\n            <p><em><
 img src="https://www.psiweb.org/images/default-source/default-album/elizab
 ethedit10cdc9ff3ad665b3a176ff00001f6b97.png?sfvrsn=d51bacdb_0&amp\;sf_site
 _temp=true&amp\;sf_site=00000000-0000-0000-0000-000000000000&amp\;MaxWidth
 =162&amp\;MaxHeight=&amp\;ScaleUp=false&amp\;Quality=High&amp\;Method=Resi
 zeFitToAreaArguments&amp\;Signature=5C1740008846BEA73DB0D9A408CA51A3" data
 -method="ResizeFitToAreaArguments" data-customsizemethodproperties="{'MaxW
 idth':'162'\,'MaxHeight':''\,'ScaleUp':false\,'Quality':'High'}" data-disp
 laymode="Custom" alt="Elizabethedit" title="Elizabethedit" /><br />\n     
        Elizabeth Garner</em></p>\n            </td>\n            <td valig
 n="top" style="width: 227px\;">\n            <p>Elizabeth Garner is a seas
 oned pharmaceutical executive with a career-long focus on addressing unsol
 ved issues and conditions that affect women&rsquo\;s health and quality of
  life. Dr. Garner is currently Chief Scientific Officer of Ferring Pharmac
 euticals US and has held previous positions as Chief Medical Officer of Ob
 sEva and Agile Therapeutics\, and senior positions at Myriad Genetics\, Ab
 bott Laboratories\, and Merck Research Labs. Beth is on the Boards of Dire
 ctors of Kezar Life Sciences and Sermonix Pharmaceuticals and is the Chair
  of the Board of NUA Surgical. She is also the Immediate Past President of
  the American Medical Women&rsquo\;s Association (AMWA)\, a professional o
 rganization whose mission is to advance women in medicine\, advocate for e
 quity\, and ensure excellence in healthcare. Dr. Garner received her M.D. 
 and M.P.H. degrees from Harvard Medical School and the Harvard School of P
 ublic Health and trained in Obstetrics and Gynecology and Gynecologic Onco
 logy at Brigham and Women&rsquo\;s and Massachusetts General Hospitals and
  the Dana Farber Cancer Institute. Beth is a frequent speaker on a range o
 f topics including the health of women\, women&rsquo\;s leadership\, and c
 linical trial diversity\; she is a 2019 and 2023 awardee of the PharmaVoic
 e 100 Most Inspiring Individuals in the life sciences industry and was the
  2022 recipient of the Woman in Science Award from AMWA.</p>\n            
 </td>\n            <td valign="top" style="width: 252px\;">\n            <
 p><strong>Opening on drug development in women's health</strong></p>\n    
         <p>Women&rsquo\;s health is defined as conditions that 1) affect w
 omen distinctly (e.g.\, endometriosis)\, 2) affect women differently (e.g.
 \, heart disease)\, and 3) affect women disproportionately (e.g.\, autoimm
 une disease). Although women make up half of the world&rsquo\;s population
 \, inclusion of women in clinical trials in the US has only been required 
 since 1993. Furthermore\, there has been a lack of investment in women&rsq
 uo\;s health research. According to McKinsey\, in 2020\, only 1% of the al
 most $200 billion in investment in healthcare research and innovation went
  toward female-specific conditions beyond oncology. The consequence of the
 se factors is that despite the exponential increase in the generation of d
 ata in health\, substantial data gaps in women&rsquo\;s health persist. In
  November 2023\, the White House announced a new initiative focused on Wom
 en&rsquo\;s Health Research. In February of this year\, Jill Biden\, who i
 s leading the White House Initiative\, announced $100 million in federal f
 unding for research and development in women&rsquo\;s health\, opening up 
 a new era in which women&rsquo\;s health is no longer considered a &ldquo\
 ;niche&rdquo\; market.</p>\n            <p>&nbsp\;</p>\n            </td>\
 n        </tr>\n        <tr>\n            <td valign="top" style="width: 1
 23px\;">\n            <p><em><img src="https://www.psiweb.org/images/defau
 lt-source/default-album/christophedit.png?sfvrsn=9314acdb_0&amp\;sf_site_t
 emp=true&amp\;sf_site=00000000-0000-0000-0000-000000000000&amp\;MaxWidth=1
 62&amp\;MaxHeight=&amp\;ScaleUp=false&amp\;Quality=High&amp\;Method=Resize
 FitToAreaArguments&amp\;Signature=8FE38F0E7BFCA7C613A343C34B293E52" data-m
 ethod="ResizeFitToAreaArguments" data-customsizemethodproperties="{'MaxWid
 th':'162'\,'MaxHeight':''\,'ScaleUp':false\,'Quality':'High'}" data-displa
 ymode="Custom" alt="Christophedit" title="Christophedit" /><br />\n       
      Christoph Gerlinger</em></p>\n            </td>\n            <td vali
 gn="top" style="width: 227px\;">\n            <p>Christoph works since mor
 e than 30 years as a statistician in the pharmaceutical industry. He is Ba
 yer&rsquo\;s expert statistician for Womens&rsquo\; Healthcare and for Hea
 lth Technology Assessment. Christoph is an EFSPI council member and since 
 over 10 years the regulatory chair of EFSPI. He is also member of several 
 scientific advisory groups for EMA and the European Commission. In his spa
 re time Christoph teaches experimental gynaecology at the Saarland State U
 niversity and leads the local chapter of the pan-European party Volt.</p>\
 n            <p>&nbsp\;</p>\n            <p>Christoph&rsquo\;s involvement
  in women&rsquo\;s health started when he joined Schering AG in 1996. His 
 Ph.D. thesis was entitled &ldquo\;Development of two methodological guidel
 ines for the evaluation of bleeding patterns &ndash\; A tool for registrat
 ion and prescription on the basis of an empirical analysis&rdquo\;. Christ
 oph (co-)authored many papers on methodological topics in women&rsquo\;s h
 ealth and he is also a co-developer of several PRO instruments in the fiel
 d of women&rsquo\;s health.</p>\n            </td>\n            <td valign
 ="top" style="width: 252px\;">\n            <p><strong>Menstrual cycle and
  Measurement of menstrual bleeding</strong></p>\n            <p>The talk w
 ill start with a brief introduction into the female menstrual cycle aimed 
 primarily at the layMEN. The assessment and statistical analysis of the no
 rmal menstrual bleeding pattern will be described. Special attention will 
 be given to changes in bleeding patterns introduced by hormonal birth cont
 rol products. First\, analyses of bleeding patterns for products with sche
 duled bleeding\, such as the classical &ldquo\;pill&rdquo\;\, will be addr
 essed. Then\, bleeding pattern analyses for products without scheduled ble
 eding\, such as intrauterine devices\, aka &ldquo\;the coil&rdquo\;\, will
  be discussed. While bleeding pattern analyses for contraceptives are typi
 cally based on simple questions like bleeding &ldquo\;yes&rdquo\; / &ldquo
 \;no&rdquo\;\, for the investigation of abnormal menstrual bleeding the ac
 tual amount of the bleeding in mL (or in uk fl oz) is of interest. Previou
 sly\, this required the collection of all items for sanitary protection\, 
 i.e.\, pads and tampons\, used during a cycle and shipping them to a labor
 atory for chemical analysis. Today\, a validated pictogram is available wh
 ere the woman rates on a simple Likert scale how soiled her sanitary prote
 ction item was. The elaboration and validation of this method will be pres
 ented.</p>\n            </td>\n        </tr>\n        <tr>\n            <t
 d valign="top" style="width: 123px\;">\n            <p><em><img src="https
 ://www.psiweb.org/images/default-source/default-album/raduedit.png?sfvrsn=
 a914acdb_0&amp\;sf_site_temp=true&amp\;sf_site=00000000-0000-0000-0000-000
 000000000&amp\;MaxWidth=162&amp\;MaxHeight=&amp\;ScaleUp=false&amp\;Qualit
 y=High&amp\;Method=ResizeFitToAreaArguments&amp\;Signature=F2D6DC8FDE4486D
 FAB17F31E2882A9F3" data-method="ResizeFitToAreaArguments" data-customsizem
 ethodproperties="{'MaxWidth':'162'\,'MaxHeight':''\,'ScaleUp':false\,'Qual
 ity':'High'}" data-displaymode="Custom" alt="Raduedit" title="Raduedit" />
 <br />\n            Radu Cimpeanu</em></p>\n            </td>\n           
  <td valign="top" style="width: 227px\;">\n            <p>Dr. Radu Cimpean
 u is Associate Professor (Reader) in Applied Mathematics at the University
  of Warwick\, specialising in the mathematical modelling of real-world sys
 tems. His primary research interests lie at the interface between fluid me
 chanics\, scientific computing and numerical solutions for partial differe
 ntial equations\, with a particular interest in knowledge transfer and ind
 ustrial mathematics (and a keen supporter of the <a href="https://eur03.sa
 felinks.protection.outlook.com/?url=https%3A%2F%2Fecmiindmath.org%2Fstudy-
 groups%2F&amp\;data=05%7C02%7C%7Cee61c644a72147dd208f08dc3773aea9%7Cfcb2b3
 7b5da0466b9b830014b67a7c78%7C0%7C0%7C638446217281688082%7CUnknown%7CTWFpbG
 Zsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7
 C0%7C%7C%7C&amp\;sdata=J7t121iqGrRuWwA5u5ZdbZ2OOe4%2FYKV4Z5Wp1OIRep4%3D&am
 p\;reserved=0">Study Groups with Industry</a> format). Radu has so far dev
 eloped methodologies used to address technologically relevant problems in 
 areas such as microfluidics\, aircraft surface de-icing and spray atomisat
 ion. He is currently Deputy Director of the <a href="https://eur03.safelin
 ks.protection.outlook.com/?url=https%3A%2F%2Fwarwick.ac.uk%2Ffac%2Fsci%2Fe
 ng%2Fresearch%2Fgrouplist%2Ffluids%2Ffdrc&amp\;data=05%7C02%7C%7Cee61c644a
 72147dd208f08dc3773aea9%7Cfcb2b37b5da0466b9b830014b67a7c78%7C0%7C0%7C63844
 6217281693564%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIi
 LCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp\;sdata=2Yb0KYdp%2BcF9ohrk8
 LE%2FP1SZGkJlLh2Z5qYoE79PxCc%3D&amp\;reserved=0">Warwick Fluid Dynamics Re
 search Centre</a>\, and Executive Committee member of the <a href="https:/
 /eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Ffluids.ac.uk%2F
 &amp\;data=05%7C02%7C%7Cee61c644a72147dd208f08dc3773aea9%7Cfcb2b37b5da0466
 b9b830014b67a7c78%7C0%7C0%7C638446217281698794%7CUnknown%7CTWFpbGZsb3d8eyJ
 WIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%
 7C&amp\;sdata=PRvy%2Bu6RCbmFHEqw6aeBPDDgsc30ZUDg9l3tSvjjiZs%3D&amp\;reserv
 ed=0">UK Fluids Network</a>\, while also supporting the UKRI National Fell
 owships in Fluid Dynamics (<a href="https://eur03.safelinks.protection.out
 look.com/?url=https%3A%2F%2Fwww.ukri.org%2Fopportunity%2Fnational-fellowsh
 ips-in-fluid-dynamics-nffdy%2F&amp\;data=05%7C02%7C%7Cee61c644a72147dd208f
 08dc3773aea9%7Cfcb2b37b5da0466b9b830014b67a7c78%7C0%7C0%7C6384462172817038
 62%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1
 haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp\;sdata=WJpmC0SdV5yAURskoSPm9gDCQK0u%2
 FsMvSp6Dv5G6TCA%3D&amp\;reserved=0">NFFDy</a>) programme.</p>\n           
  </td>\n            <td valign="top" style="width: 252px\;">\n            
 <p><strong>A new flow-based design for double-lumen needles in IVF</strong
 ><br />\n            <br />\n            Oocyte retrieval forms a crucial 
 part of in vitro fertilisation treatment and its ultimate outcome. Standar
 d double-lumen needles\, which include a sequence of aspiration and flushi
 ng steps\, are characterised by a similar success rate to single-lumen nee
 dles\, despite their increased cost. In this talk I will present a novel h
 ydrodynamics-based needle called <a href="https://eur03.safelinks.protecti
 on.outlook.com/?url=https%3A%2F%2Fpatents.google.com%2Fpatent%2FUS20220323
 112A1%2Fen&amp\;data=05%7C02%7C%7Cee61c644a72147dd208f08dc3773aea9%7Cfcb2b
 37b5da0466b9b830014b67a7c78%7C0%7C0%7C638446217281666749%7CUnknown%7CTWFpb
 GZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%
 7C0%7C%7C%7C&amp\;sdata=3uPVrRN57VqxDnHdKf7%2BnumY%2BwoX1CBXF7FWcY6xg3w%3D
 &amp\;reserved=0" title="https://patents.google.com/patent/US20220323112A1
 /en">the OxIVF needle</a>\, with design features that enablethe generation
  of an internal flow field within the full follicular volume via laterally
 \, rather than frontally\, oriented flushing\, leading to successful retri
 evals with no additional stress on the oocyte. An in-silico mathematical m
 odel (<a href="https://eur03.safelinks.protection.outlook.com/?url=https%3
 A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS0021929023004037
 &amp\;data=05%7C02%7C%7Cee61c644a72147dd208f08dc3773aea9%7Cfcb2b37b5da0466
 b9b830014b67a7c78%7C0%7C0%7C638446217281675994%7CUnknown%7CTWFpbGZsb3d8eyJ
 WIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%
 7C&amp\;sdata=WHveJwOgEoDYhIND5SOg%2FyYN6OXYkKhnFh7AHGcMxGs%3D&amp\;reserv
 ed=0" title="https://www.sciencedirect.com/science/article/pii/S0021929023
 004037">J. Biomechanics 160\, 111832\, 2023</a>) based on multi-phase flow
  direct numerical simulation provides new insight into the internal flow m
 ovement as part of the constructed digital twin\, while forces measured du
 ring these tests showcase how the oocyte experiences stresses which are no
  larger than at the aspiration point\, with the flow field providing a gen
 tle steering effect towards the extraction region. We found that the propo
 sed framework increases oocyte yield to up to 100% in computational studie
 s\, marking a significant improvement over the traditional double-lumen de
 sign whose success rate of no more than 75% in like-for-like comparisons w
 as also highly dependent on the location of the needle tip inside the foll
 icle. This design unlocks new capabilities in both human and veterinary co
 ntexts\, with preliminary studies showing significant promise (<a href="ht
 tps://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.scienc
 edirect.com%2Fscience%2Farticle%2Fpii%2FS2772283X23006507&amp\;data=05%7C0
 2%7C%7Cee61c644a72147dd208f08dc3773aea9%7Cfcb2b37b5da0466b9b830014b67a7c78
 %7C0%7C0%7C638446217281682470%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAi
 LCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp\;sdata=Obu
 oH%2BFZtUseQwqiRLt6OWcwiKD%2FQgdYWGA2jiEwcVI%3D&amp\;reserved=0" title="ht
 tps://www.sciencedirect.com/science/article/pii/S2772283X23006507">Animal 
 - science Proc. 14 (3)\, 468-469\, 2023</a>). The interdisciplinary approa
 ch and research team dynamics\, which underpinned many of the advances abo
 ve\, will also be brought to the forefront as the scientific milestones of
  the study are expanded upon. Acknowledgments: Alfonso A. Castrej&oacute\;
 n-Pita (University of Oxford)\, Lee Nai Lim (Oxford University Hospital)\,
  Manu Vatish (University of Oxford) and Ektoras X. Georgiou (Oxford Univer
 sity Hospital).</p>\n            </td>\n        </tr>\n        <tr>\n     
        <td valign="top" style="width: 123px\;"><img src="https://www.psiwe
 b.org/images/default-source/default-album/jackedit.png?sfvrsn=3f1aacdb_0&a
 mp\;sf_site_temp=true&amp\;sf_site=00000000-0000-0000-0000-000000000000&am
 p\;MaxWidth=162&amp\;MaxHeight=&amp\;ScaleUp=false&amp\;Quality=High&amp\;
 Method=ResizeFitToAreaArguments&amp\;Signature=8FF78474B5DEF03299594387DBE
 05269" data-method="ResizeFitToAreaArguments" data-customsizemethodpropert
 ies="{'MaxWidth':'162'\,'MaxHeight':''\,'ScaleUp':false\,'Quality':'High'}
 " data-displaymode="Custom" alt="Jackedit" title="Jackedit" />&nbsp\;<em>J
 ack Wilkinson</em></td>\n            <td valign="top" style="width: 227px\
 ;">\n            <p>Jack Wilkinson is a Senior Lecturer in the Centre for 
 Biostatistics\, University of Manchester. His research interests cover bot
 h the application\, development\, and criticism of methods for the evaluat
 ion of health interventions\, with a particular interest in interventions 
 for the treatment of subfertility\, including assisted reproductive techno
 logies (ART). He holds Statistics or Methodological Editor roles for Cochr
 ane Gynaecology and Fertility\, BJOG: An International Journal of Obstetri
 cs and Gynaecology\, Fertility and Sterility and Reproduction and Fertilit
 y. He is currently leading the NIHR-funded INSPECT-SR project\, which aims
  to develop a tool for identifying &lsquo\;problematic&rsquo\; randomised 
 controlled trials\, including those subject to data fabrication or falsifi
 cation.</p>\n            </td>\n            <td valign="top" style="width:
  252px\;"><strong>IVF &ndash\; statistical challenges in complex\, multist
 age interventions - Jack Wilkinson (Manchester University)<br />\n        
     </strong>\n            <p>Assisted Reproductive Technologies (ART) are
  complex multi-stage interventions\, typically involving stimulation of ov
 aries and collection of eggs\, the fertilisation of eggs to make embryos\,
  the culture and subsequent selection of embryos using some form of algori
 thm\, followed by an embryo transfer with the aim of producing a pregnancy
  and subsequent live birth of a healthy infant. The multistage nature of A
 RT introduces a number of challenges for the design and analysis of both r
 andomised and non-randomised studies of fertility interventions\, and some
  apparently &lsquo\;common-sense&rsquo\; analysis choices correspond to no
  clinically relevant estimand. In this talk\, I will give a non-technical 
 overview of some recurring methodological pitfalls in ART intervention res
 earch.</p>\n            </td>\n        </tr>\n    </tbody>\n</table>\n<p>&
 nbsp\;</p>\n<div><em><br />\n</em></div>
END:VEVENT
END:VCALENDAR
